Monday 27 April 2015, Royal Marsden Hospital, London
1-day course: Targeted treatments for lung cancer and urological cancers
Description: This course provides a broad overview of the cells, genes, proteins and pathways that drive non-small cell lung cancer (NSCLC), prostate cancer and kidney cancer. This includes: the role of fusion proteins and androgen receptor signalling in prostate cancer; VHL mutations and angiogenesis in kidney cancer; signalling pathways known to be at fault in NSCLC.
The course includes the rationale behind many different targeted treatment approaches in use and in development for these cancers, including recent advances in immunotherapies for lung, prostate, kidney and bladder cancer.
As ever, I will explain all the relevant scientific concepts for a non-scientific audience.
Audience: Ideal for doctors of all levels, experienced research nurses and clinical trials/drug development staff with a science degree; requires some understanding of concepts such as genes, DNA and cell biology; some knowledge of cell signalling would be an advantage.
- The role of DNA damage & epigenetics in cancer development
- Intra-tumoural heterogeneity & the cancer microenvironment
- Monoclonal antibodies and kinase inhibitors: spot the difference
- Cellular, molecular and genetic makeup
- Interaction between the androgen receptor and other signalling pathways
- Hormone therapies: old and new inhibitors of androgens and androgen receptor signalling (eg. LHRH agonists & antagonists, enzalutimide, abiraterone)
- Novel targets: EGFR, IGF-1R, PDGFR, angiogenesis, mTOR, PARP
- Targeting the bone: radium223, denosumab, MET inhibitors
- Introducing the main subtypes of renal cell carcinoma: clear cell, papillary and chromophobe
- Genetic mutations and signalling pathways associated with clear cell kidney cancer
- Angiogenesis inhibitors and mTOR inhibitors for kidney cancer
- Mechanisms of development and the molecular landscape
- The role of the EGF-Receptor
- EGF-R targeted treatments (gefitinib, erlotinib, afatinib, dacomitinib)
- ALK inhibitors (crizotinib & LDK378)
- More targets and treatments: BRAF, PI3K, & MEK inhibitors; VEGFR & multi-kinase inhibitors; PARP inhibitors for NSCLC and small cell lung cancer
- Cell-based therapies
- Checkpoint inhibitors (CTLA-4, PD-1 and PDL-1 monoclonal antibodies)